<DOC>
	<DOCNO>NCT00605345</DOCNO>
	<brief_summary>This two arm study compare efficacy safety subcutaneous Mircera versus darbepoetin alfa maintenance hemoglobin level kidney transplant recipient chronic renal anemia . Patients currently receive maintenance treatment darbepoetin alfa randomize either receive 4-weekly injection Mircera start dose ( 120 , 200 360 microgram subcutaneously ) derive dose darbepoetin alfa receive 2 week precede study start , stay 2-weekly darbepoetin alfa therapy . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Comparing Subcutaneous Mircera Darbepoetin Alfa Maintenance Treatment Anemia Kidney Transplant Recipients .</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>adult patient , &gt; = 18 year age ; kidney transplant recipient stage 3 stage 4 chronic kidney disease ; function graft &gt; 6 month &lt; 10 year kidney transplantation , sign acute rejection ; stable maintenance subcutaneous darbepoetin alfa therapy every 2 week . transfusion red blood cell previous 2 month ; poorly control hypertension ; significant acute chronic bleeding ; need dialysis therapy expect next 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>